Literature DB >> 1770006

Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain.

J A Allan1, R M Hembry, S Angal, J J Reynolds, G Murphy.   

Abstract

A specific high-titre polyclonal antiserum to recombinant human prostromelysin was raised in a sheep and shown by immunoblotting to detect latent prostromelysin, high and low Mr active forms and the C-terminal domain. This antiserum was used to demonstrate by indirect immunofluorescence that latent and active high Mr prostromelysin bind to reconstituted collagen fibrils, and to other extracellular matrix components in tissues ex vivo but that active low Mr stromelysin does not. Isolation of the C-terminal domain was carried out to demonstrate that stromelysin binding was through this domain. By use of an antiserum to the tissue inhibitor of metalloproteinases (TIMP) it was shown that TIMP is unable to bind to reconstituted collagen fibrils. TIMP, however, will bind when active high Mr stromelysin is present but not if latent prostromelysin is bound. We conclude that stromelysin has different binding specificities from those previously documented for collagenase; only active collagenase binds to reconstituted collagen fibrils. However, TIMP binds to the active forms of both stromelysin and collagenase when these are bound to the collagen fibrils. These results have important implications for the interpretation of immunolocalization data in establishing the roles of metalloproteinases and their inhibitors in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1770006     DOI: 10.1242/jcs.99.4.789

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  22 in total

1.  Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone.

Authors:  S Bord; A Horner; R M Hembry; J J Reynolds; J E Compston
Journal:  J Anat       Date:  1997-07       Impact factor: 2.610

Review 2.  Progress in matrix metalloproteinase research.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Mol Aspects Med       Date:  2008-05-24

Review 3.  Matrix metalloproteinase collagenolysis in health and disease.

Authors:  Sabrina Amar; Lyndsay Smith; Gregg B Fields
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-04-26       Impact factor: 4.739

Review 4.  Review collagen-based biomaterials for wound healing.

Authors:  Sayani Chattopadhyay; Ronald T Raines
Journal:  Biopolymers       Date:  2014-08       Impact factor: 2.505

5.  The interface between catalytic and hemopexin domains in matrix metalloproteinase-1 conceals a collagen binding exosite.

Authors:  Laurence H Arnold; Louise E Butt; Stephen H Prior; Christopher M Read; Gregg B Fields; Andrew R Pickford
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

6.  Matrix metalloproteinases in the formation of human synovial joint cavities.

Authors:  J C Edwards; L S Wilkinson; P Soothill; R M Hembry; G Murphy; J J Reynolds
Journal:  J Anat       Date:  1996-04       Impact factor: 2.610

7.  Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine.

Authors:  C J Bailey; R M Hembry; A Alexander; M H Irving; M E Grant; C A Shuttleworth
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

8.  Fragmentation of human polymorphonuclear-leucocyte collagenase.

Authors:  V Knäuper; A Osthues; Y A DeClerck; K E Langley; J Bläser; H Tschesche
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

9.  Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain.

Authors:  A J Fosang; K Last; V Knäuper; P J Neame; G Murphy; T E Hardingham; H Tschesche; J A Hamilton
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

10.  Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity.

Authors:  Janelle L Lauer-Fields; Michael J Chalmers; Scott A Busby; Dmitriy Minond; Patrick R Griffin; Gregg B Fields
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.